These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32613835)

  • 1. Systemic Delivery of Aptamer-Conjugated XBP1 siRNA Nanoparticles for Efficient Suppression of HER2+ Breast Cancer.
    Zhang L; Mu C; Zhang T; Wang Y; Wang Y; Fan L; Liu C; Chen H; Shen J; Wei K; Li H
    ACS Appl Mater Interfaces; 2020 Jul; 12(29):32360-32371. PubMed ID: 32613835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of targeted therapy therapeutics to sensitize triple-negative breast cancer chemosensitivity utilizing bacteriophage phi29 derived packaging RNA.
    Zhang L; Mu C; Zhang T; Yang D; Wang C; Chen Q; Tang L; Fan L; Liu C; Shen J; Li H
    J Nanobiotechnology; 2021 Jan; 19(1):13. PubMed ID: 33413427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology.
    Shu D; Li H; Shu Y; Xiong G; Carson WE; Haque F; Xu R; Guo P
    ACS Nano; 2015 Oct; 9(10):9731-40. PubMed ID: 26387848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.
    Thiel KW; Hernandez LI; Dassie JP; Thiel WH; Liu X; Stockdale KR; Rothman AM; Hernandez FJ; McNamara JO; Giangrande PH
    Nucleic Acids Res; 2012 Jul; 40(13):6319-37. PubMed ID: 22467215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
    Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
    Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway.
    Chen X; Iliopoulos D; Zhang Q; Tang Q; Greenblatt MB; Hatziapostolou M; Lim E; Tam WL; Ni M; Chen Y; Mai J; Shen H; Hu DZ; Adoro S; Hu B; Song M; Tan C; Landis MD; Ferrari M; Shin SJ; Brown M; Chang JC; Liu XS; Glimcher LH
    Nature; 2014 Apr; 508(7494):103-107. PubMed ID: 24670641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
    Dou S; Yang XZ; Xiong MH; Sun CY; Yao YD; Zhu YH; Wang J
    Adv Healthc Mater; 2014 Nov; 3(11):1792-803. PubMed ID: 24947820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Mucin1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and IGF-1R siRNA to SKBR3 Metastatic Breast Cancer Cells.
    Jafari R; Majidi Zolbanin N; Majidi J; Atyabi F; Yousefi M; Jadidi-Niaragh F; Aghebati-Maleki L; Shanehbandi D; Soltani Zangbar MS; Rafatpanah H
    Iran Biomed J; 2019 Jan; 23(1):21-33. PubMed ID: 30041514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy.
    Jeong HY; Kim H; Lee M; Hong J; Lee JH; Kim J; Choi MJ; Park YS; Kim SC
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33371333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment.
    Hu G; Chun X; Wang Y; He Q; Gao H
    Oncotarget; 2015 Dec; 6(38):41258-74. PubMed ID: 26517810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic nanocarriers for the specific delivery of siRNA: Contribution of breast cancer cells active targeting for down-regulation efficiency.
    Bruniaux J; Allard-Vannier E; Aubrey N; Lakhrif Z; Ben Djemaa S; Eljack S; Marchais H; Hervé-Aubert K; Chourpa I; David S
    Int J Pharm; 2019 Oct; 569():118572. PubMed ID: 31352052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Administration of siRNA with Anti-HB-EGF Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer.
    Okamoto A; Asai T; Hirai Y; Shimizu K; Koide H; Minamino T; Oku N
    Mol Pharm; 2018 Apr; 15(4):1495-1504. PubMed ID: 29502423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth.
    Xue L; Maihle NJ; Yu X; Tang SC; Liu HY
    Mol Pharm; 2018 Nov; 15(11):4801-4813. PubMed ID: 30222359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
    Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
    Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A self-assembled RNA-triple helix hydrogel drug delivery system targeting triple-negative breast cancer.
    Ding L; Li J; Wu C; Yan F; Li X; Zhang S
    J Mater Chem B; 2020 Apr; 8(16):3527-3533. PubMed ID: 31737891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic delivery of siRNA by T7 peptide modified core-shell nanoparticles for targeted therapy of breast cancer.
    Yu MZ; Pang WH; Yang T; Wang JC; Wei L; Qiu C; Wu YF; Liu WZ; Wei W; Guo XY; Zhang Q
    Eur J Pharm Sci; 2016 Sep; 92():39-48. PubMed ID: 27355138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aptamer-conjugated and doxorubicin-loaded grapefruit-derived nanovectors for targeted therapy against HER2
    Tang Z; Jun Y; Lv Y; Li Y; Zhang Z; Tao M; Chen X; He J; Zhang L; Wang QL
    J Drug Target; 2020 Feb; 28(2):186-194. PubMed ID: 31134823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted siRNA delivery by anti-HER2 antibody-modified nanoparticles of mPEG-chitosan diblock copolymer.
    Wang Y; Liu P; Du J; Sun Y; Li F; Duan Y
    J Biomater Sci Polym Ed; 2013; 24(10):1219-32. PubMed ID: 23713424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133.
    Yin H; Xiong G; Guo S; Xu C; Xu R; Guo P; Shu D
    Mol Ther; 2019 Jul; 27(7):1252-1261. PubMed ID: 31085078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer.
    Parvani JG; Gujrati MD; Mack MA; Schiemann WP; Lu ZR
    Cancer Res; 2015 Jun; 75(11):2316-2325. PubMed ID: 25858145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.